Oppenheimer Asset Management Inc. Reduces Stock Holdings in Stryker Corporation $SYK

Key Points

• Oppenheimer Asset Management trimmed its Stryker stake by 26.9% in Q4, selling 8,696 shares and now holding 23,641 shares valued at about $8.31 million.
• Stryker missed Q1 estimates—adjusted EPS of $2.60 vs. ~$2.98 expected and revenue of $6.02B vs. ~$6.34B—management cited a cyber incident as the primary cause, though the company maintained FY‑2026 guidance of $14.90–$15.10 EPS; the stock fell roughly 6.3%.
• Director Ronda E. Stryker sold 250,000 shares at an average of $362.92 (≈$90.73M), reducing her position by about 9.23%; insiders still own ~4.6% of the company while institutions own ~77%.

Oppenheimer Asset Management Inc. trimmed its holdings in shares of Stryker Corporation (NYSE:SYK - Free Report) by 26.9% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 23,641 shares of the medical technology company's stock after selling 8,696 shares during the quarter. Oppenheimer Asset Management Inc.'s holdings in Stryker were worth $8,309,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in SYK. Brighton Jones LLC grew its stake in Stryker by 15.4% during the 4th quarter. Brighton Jones LLC now owns 4,564 shares of the medical technology company's stock valued at $1,643,000 after purchasing an additional 609 shares during the last quarter. Schnieders Capital Management LLC. purchased a new stake in Stryker during the 2nd quarter valued at about $205,000. Marshall Wace LLP grew its stake in Stryker by 107.9% during the 2nd quarter. Marshall Wace LLP now owns 5,700 shares of the medical technology company's stock valued at $2,255,000 after purchasing an additional 77,831 shares during the last quarter. Nebula Research & Development LLC purchased a new stake in Stryker during the 2nd quarter valued at about $219,000. Finally, HUB Investment Partners LLC purchased a new stake in Stryker during the 2nd quarter valued at about $253,000. 77.09% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several research firms have weighed in on SYK. Piper Sandler reiterated an "overweight" rating on shares of Stryker in a research note on Tuesday, January 27th. Leerink Partners began coverage on Stryker in a research note on Monday, April 13th. They set an "outperform" rating and a $410.00 price target on the stock. Truist Financial lowered their target price on Stryker from $395.00 to $380.00 and set a "hold" rating on the stock in a research note on Wednesday, April 15th. Deutsche Bank Aktiengesellschaft set a $315.00 target price on Stryker in a research note on Friday. Finally, Robert W. Baird set a $385.00 target price on Stryker in a research note on Friday. Sixteen research analysts have rated the stock with a Buy rating and six have given a Hold rating to the company's stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $401.43.

Insiders Place Their Bets

In related news, Director Ronda E. Stryker sold 250,000 shares of the company's stock in a transaction dated Wednesday, February 4th. The stock was sold at an average price of $362.92, for a total value of $90,730,000.00. Following the completion of the transaction, the director owned 2,457,331 shares of the company's stock, valued at approximately $891,814,566.52. This represents a 9.23% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 4.60% of the company's stock.

Stryker Stock Down 6.3%

Shares of SYK opened at $295.43 on Friday. Stryker Corporation has a 52 week low of $294.55 and a 52 week high of $404.87. The company has a quick ratio of 1.21, a current ratio of 1.89 and a debt-to-equity ratio of 0.66. The company has a market capitalization of $113.15 billion, a price-to-earnings ratio of 35.17, a PEG ratio of 1.84 and a beta of 0.92. The stock's 50-day moving average price is $345.67 and its 200-day moving average price is $356.95.

Stryker (NYSE:SYK - Get Free Report) last issued its earnings results on Thursday, April 30th. The medical technology company reported $2.60 EPS for the quarter, missing analysts' consensus estimates of $2.98 by ($0.38). Stryker had a return on equity of 23.74% and a net margin of 13.20%.The company had revenue of $6.02 billion during the quarter, compared to analysts' expectations of $6.34 billion. During the same quarter in the previous year, the company earned $2.84 EPS. The firm's quarterly revenue was up 2.6% compared to the same quarter last year. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. On average, sell-side analysts predict that Stryker Corporation will post 14.91 EPS for the current year.

Stryker Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Thursday, April 30th. Investors of record on Tuesday, March 31st were issued a $0.88 dividend. The ex-dividend date of this dividend was Tuesday, March 31st. This represents a $3.52 dividend on an annualized basis and a yield of 1.2%. Stryker's dividend payout ratio is presently 41.90%.

Key Stryker News

Here are the key news stories impacting Stryker this week:

• Positive Sentiment: Stryker maintained its FY‑2026 outlook — $14.90–$15.10 adjusted EPS and 8%–9.5% organic sales growth — signaling management’s confidence in recovery from the cyber incident. Article Title
• Positive Sentiment: Operational cash flow and net income showed notable improvement year-over-year (operating cash flow jumped and net income rose), which supports longer‑term cash generation and capital investment. Article Title
• Neutral Sentiment: Stryker will present at the Bank of America Global Healthcare Conference on May 13 — an opportunity for management to address the cyber recovery and investor questions, but not an immediate catalyst for results. Article Title
• Negative Sentiment: Q1 results missed consensus: adjusted EPS of $2.60 vs. ~ $2.98 expected and revenue of $6.02B vs. ~$6.34B. Management cited a cyber incident that disrupted production, pressured margins and slowed growth — the primary driver of today’s selling pressure. Article Title
• Negative Sentiment: Several Wall Street firms cut Stryker price targets this morning (JPMorgan to $400, Wells Fargo to $418, Needham/BTIG lowered targets) — ratings largely remain buy/overweight but lower targets reduce near‑term upside expectations and add selling pressure. Article Title

Stryker Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons' offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.